Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine
| Autor: | Anatoly Dritschilo, Prafulla C. Gokhale, Chuanbo Zhang, Imran Ahmad, Usha Kasid, Jin Pei, Aquilur Rahman |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Cancer Research Radiosensitizer medicine.medical_treatment Mice Nude Docetaxel Pharmacology Deoxycytidine Mice chemistry.chemical_compound Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Pharmacology (medical) Epirubicin Cisplatin Mitoxantrone Chemotherapy business.industry Oligonucleotides Antisense Xenograft Model Antitumor Assays Gemcitabine Proto-Oncogene Proteins c-raf Oncology chemistry Liposomes Female Taxoids business medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 15:243-253 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/00001813-200403000-00009 |
| Popis: | Raf-1 protein serine/threonine kinase plays an important role in cell proliferation and cell survival. We have previously described a novel cationic liposome-entrapped formulation of raf antisense oligodeoxyribonucleotide (LErafAON) and its use as a radiosensitizer. The aim of this study was to examine the effect of combination of LErafAON and a chemotherapeutic agent on growth of human prostate (PC-3) and pancreatic tumor xenografts in athymic mice (Aspc-1 and Colo 357). In PC-3 tumor-bearing mice, administration of a combination of LErafAON (i.v., 25 mg/kg/dose, x10/16) and cisplatin (i.v., 11.0 mg/kg/dose, x3), epirubicin (EPI) (i.v., 9.0 mg/kg/dose, x3) or mitoxantrone (MTO) (i.v., 2.5 mg/kg/dose, x3) led to enhanced tumor growth inhibition as compared with single agents (LErafAON+cisplatin versus cisplatin, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|